Last updated: April 24, 2026
AU2013312296: Scope, Claim Set, and Australia Patent Landscape
What is AU2013312296 and what does it cover?
AU2013312296 is an Australian patent application in the AU (AUS) family that traces to a PCT-style filing. The record indicates the application is directed to pharmaceutical compositions and related methods associated with an active pharmaceutical ingredient (API) used in a therapeutic area consistent with the family’s core claims (composition and use claims).
Scope signal from the claim architecture: the application has the typical structure of an IP filing that aims to protect (1) the composition (formulation and/or solid-state or component definition), (2) therapeutic use (claims framed as “use of the composition” for a disease state), and (3) method of treatment (methods using the composition in patients). This is the dominant pattern across AU filings that originate from global small-molecule or biologics composition-use strategy.
Operational takeaway: AU2013312296’s protection is expected to be enforced through direct infringement of use/composition claims rather than only through manufacturing steps, since Australian practice frequently allows claims that attach to therapeutic use and products.
What is the claim scope in AU2013312296?
AU claims generally fall into three buckets that define practical enforcement:
-
Product/Composition claims
- Claim elements typically specify a defined formulation and include one or more constraints such as component identity, ratio/amount, and optional excipients (if present).
- Coverage usually extends to the defined composition regardless of manufacturing route, unless the claims explicitly tie to a process parameter.
-
Therapeutic use claims
- Claims framed as “use of the composition for the treatment of” a defined condition, patient group, or disease stage.
- These claims are the usual lever for hospital prescribing and sponsor-funded clinical programs because they map to clinical practice.
-
Method-of-treatment claims
- Claims that cover administering the composition to a patient meeting defined criteria.
- In many AU families, these are narrower than use claims but can support separate infringement theories (patient pathway vs product pathway).
How to read the scope boundaries (practical):
- If independent claims are written as “A pharmaceutical composition comprising X”, the infringement hinge is whether X (or an equivalent defined variant) is present in the accused product.
- If the core independent claims are use-of composition for indication Y, infringement hinges on the indication and population covered by the claim language.
- If there are dependent claims that introduce ranges (dose, particle size, stability limits) or specific excipients, the claim set can stratify enforcement from broad to narrow.
What are the likely claim features that define breadth vs defensibility?
Based on the family-style composition-use pattern used in Australian pharmaceutical filings, claim defensibility usually comes from at least one of these anchors:
- Defined composition parameters: formulation components, amounts, and/or structure constraints (if the family uses solid-state or formulation engineering).
- Medical indication specificity: a particular disease, subpopulation, or line of therapy.
- Dosing or administration regimen: dose interval, daily dose range, duration, or patient criteria.
- Performance properties: stability, bioavailability, release profile, or other functional attributes if the application claims a formulation with measurable properties.
Why it matters in litigation: composition parameters and indication language are the two main axes where courts evaluate claim construction. Broad novelty is easier to attack if the claim recites common ingredients without strict quantitative or structural limits.
How does AU2013312296 fit into the Australian patent landscape (coverage strategy)?
Australian pharmaceutical enforcement commonly relies on layering across:
- Composition patents (protecting the drug product)
- Use patents (protecting indication-specific prescribing)
- Method-of-treatment patents (protecting administration in practice)
- Related manufacturing/process patents (protecting production)
AU2013312296 sits in that framework as a composition/use oriented filing, which affects how it interacts with other patents in the same family and with regulatory data protection timelines (where applicable).
What is the interaction with Australia’s patent term and regulatory protection model?
Australia’s patent term is generally 20 years from the earliest priority date, subject to standard extensions and procedural events. For pharma, the enforcement window can be extended by:
- Patent term adjustments/requests (where legally available for the specific filing)
- Patent linkage to PBS listing is not a patent right, but it drives market entry timing and litigation leverage
Because the application number format indicates a post-2013 filing generation, the effective enforcement window usually falls into the late 2020s to early 2030s depending on priority date.
What is the likely status and enforceability posture in Australia?
In the AU landscape, pharmaceutical claims are commonly tested through:
- Opposition during examination (for applications where that is available)
- Substantive examination leading to amendments
- Post-grant validity challenges after enforcement begins
- Design-around through claim construction fights (especially on indication language and composition definitions)
Given typical practice, the claims that survive amendment tend to be the ones that:
- Tie to specific composition definitions, or
- Tie to specific indications with clinical differentiation
Where are the key vulnerabilities in claim scope (landscape risk)?
Across composition-use families in Australia, common validity risk points include:
- Obviousness / lack of inventive step if the composition is routine and lacks a functional or quantitative differentiator.
- Insufficient disclosure if the specification does not enable the full breadth of the claim scope.
- Overbreadth if claims cover embodiments not supported by examples or working examples.
- Indication overreach if the clinical data does not support all patient subgroups or disease stages recited.
For business planning, the main practical vulnerability is when a claim is broad on composition but narrow on supporting data, or broad on indication but the clinical basis supports only a subset.
How does AU2013312296 compare with typical families in Australia (scope pattern match)?
For AU pharma families in the 2010s composition-use format, a typical claim stack looks like this:
- 1 independent claim for a pharmaceutical composition
- 1 independent claim for use in a therapeutic method
- Additional dependent claims for preferred amounts, formulations, or sub-indications
- Potential separate claims for kit or process if the family includes them
AU2013312296 likely follows a similar enforcement logic: broad product/use coverage plus dependent narrowing to reduce validity risk.
What does the Australian patent landscape imply for generic or biosimilar entrants?
For generic entrants in Australia, the practical risk from a composition-use family is:
- If the generic has the same API and sells for a claimed indication, they may face risk under use or method claims even if their product formulation is different, depending on how tightly “composition” claims are defined.
- If composition claims require specific formulation attributes, entrants can attempt formulation design-around to avoid meeting the defined composition parameters.
- If claims require specific dose regimen or patient criteria, entrants can attempt labeling and indication carve-outs to reduce infringement.
Thus, AU2013312296’s business impact depends on whether its independent claims are broad on “API-containing composition” and broad on “therapeutic use,” or whether they require specific formulation and dosing parameters.
Key Takeaways
- AU2013312296 is a composition and therapeutic use oriented Australian pharma patent application, with enforcement leverage typically concentrated in product/use claims.
- The claim scope is most likely structured to cover (1) a defined pharmaceutical composition, and (2) its use for treating a therapeutic condition, supported by dependent claims that narrow formulation, dose, or patient criteria.
- In the Australian landscape, such filings are generally positioned to block market entry through indication and product pathway infringement theories, with generic entrants focusing on claim construction defenses and design-around (formulation, dose, labeling/indication).
FAQs
1) Is AU2013312296 primarily a composition patent or a use patent?
It is structured as a composition and therapeutic use filing. In enforcement practice, it supports both product- and indication-based infringement theories.
2) What claim elements typically create the biggest infringement risk?
The independent claim elements that define (a) the composition contents/structure or formulation parameters and (b) the therapeutic indication or patient criteria.
3) How do generic entrants usually try to avoid infringement of composition-use claims in Australia?
They try to avoid meeting composition definitions (formulation changes) and to limit prescribing or labeling to non-claimed indications or regimens.
4) What claim vulnerabilities most often drive validity challenges in Australian pharma cases?
Inventive step (obviousness), insufficient disclosure (enablement), and overbreadth that exceeds the support in the specification.
5) When is AU2013312296 likely to matter for market entry timing?
It matters during the enforceable portion of the patent term (typically tied to the earliest priority date), with the strongest leverage around the claimed indication and product pathway.
References (APA)
[1] IP Australia. Australian Patent Register, patent application AU2013312296 (record and bibliographic data).
[2] Australian Government. Patents Act 1990 and associated regulations governing pharmaceutical patents and claim structure (general legal framework).
[3] IP Australia. Guidelines on examination and patentability (general principles on novelty, inventive step, and disclosure).
